This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dogs of the Dow's 'Mutts' Have No Bite

NEW YORK ( TheStreet) -- At the beginning of every year, proponents of the "Dogs of the Dow" investment strategy trot out the 10 highest-yielding stocks in the Dow Jones Industrial Average and suggest buying them as a means of beating the market.

Although every dog has its day, there are always some perennial losers in the pack, in terms of return on investment, so strictly hewing to that strategy has its faults.

For example, 2010 was the first year since 2006 when the Dogs' return outdid that of the Dow, excluding dividends. The group has only done it three times in the past eight years, and only in 2006, when the Dogs returned 30% vs. the 19% of the Dow, was it a blowout victory.

But 2010 was also a very strong year for the Dow Dogs' strategy, as the group returned an average 16.3%, while the blue-chip index returned 11%.

The average 3.87% yield the class of 2010 paid in dividends also makes the Dogs of the Dow strategy worth considering.

But every year there are a couple of mutts among the Dogs that investors would have best avoided. Lately, they've been from the health care sector, one of the poorest-performing groups in 2010 with a return of 6.5%, which is next to last out of all investment sectors.

In 2010, the Dogs were held back by pharmaceutical giants Pfizer (PFE - Get Report), down 3.7% on the year, and Merck (MRK - Get Report), off 1.4%. A newcomer to the Dogs that's going on the list for 2011, health care products conglomerate Johnson & Johnson (JNJ - Get Report), was right in step, losing 4% in 2010.

And yet analysts are fond of these stocks because of their long-term prospects, which are built on the idea that a glut of baby boomers, now edging into retirement, will gobble an ever-increasing number of drugs as they age. The elderly currently account for about one-third of drug industry sales.

So we decided to look at the prospects for those three companies, as well as two of their competitors that face similar challenges.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG
ABT $46.54 -0.66%
BAX $68.91 -1.06%
JNJ $99.17 -0.33%
MRK $60.26 -0.38%
PFE $33.46 -1.12%

Markets

DOW 17,841.98 -86.22 -0.48%
S&P 500 2,080.15 -9.31 -0.45%
NASDAQ 4,919.6440 -19.6830 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs